Jeffrey S. Farrow - 15 Jun 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Reporting relationship: Chief Financial Officer and Chief Strategy Officer
Issuer ticker: TARS
Reported as of: 15 Jun 2026
Net transaction value: -$877,436
SEC form: 4
Accepted by SEC: 17 Jun 2026, 16:17:35 UTC
Prior SEC filing: 02 Jun 2026
Next SEC filing: 29 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Farrow

Key filing fact

Jeffrey S. Farrow filed Form 4 for Tarsus Pharmaceuticals, Inc. (TARS) on 17 Jun 2026.

Key facts

This page summarizes Jeffrey S. Farrow's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2026, 16:17.

Change

Previous filing in this sequence was filed on 02 Jun 2026.
Current net transaction value: -$877,436.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001405253 Primary reporting owner

Farrow Jeffrey S

Relationship: Chief Financial Officer and Chief Strategy Officer
Address: C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE
Signature: /s/ Jeffrey Farrow
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TARS transaction

Common Stock

Options Exercise

Transaction value
Shares: +27,881
Change %: +64%
Price
Shares after: 71,197
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1

TARS transaction

Common Stock

Sale

Transaction value: $877,436
Shares: -14,396
Change %: -20%
Price: $60.95
Shares after: 56,801
Date: 16 Jun 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -27,881
Change %: -50%
Price: $0.000000^*
Shares after: 27,882
Date: 15 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,881
Exercise price
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

Footnote F2

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Footnote F3

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

Footnote F4

RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

SEC remarks

Chief Financial Officer and Chief Strategy Officer